Last reviewed · How we verify
Draxxin (TULATHROMYCIN)
Draxxin (Tulathromycin) is a small molecule antibiotic developed by Pfizer and currently owned by Zoetis. It is used to treat respiratory infections in cattle and swine. Draxxin works by inhibiting protein synthesis in bacteria, ultimately leading to bacterial cell death. It is a patented product, and its commercial status is subject to change. Key safety considerations include potential side effects such as injection site reactions and changes in milk production in lactating dairy cattle.
At a glance
| Generic name | TULATHROMYCIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Draxxin CI brief — competitive landscape report
- Draxxin updates RSS · CI watch RSS